# A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

> **NCT00889382** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 152 (actual)

## Conditions studied

- Ovarian Cancer
- Solid Tumors

## Interventions

- **DRUG:** OSI-906
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00889382
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-05
- **Primary completion:** 2014-08-01
- **Final completion:** 2014-08-25
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889382, "A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00889382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*